

March 14, 2025

Nissan Chemical and RaQualia Pharma Enter into License Agreement to Research for Neurological Therapeutics

Nissan Chemical Corporation (Head office: Tokyo, Japan, President: Shinsuke Yagi) and RaQualia Pharma (Head office: Aichi, Japan, President: Masaki Sudo) announced today the signing of a license agreement to research, develop and commercialize novel neurological therapeutics identified by Nissan Chemical.



Nissan Chemical has continued putting efforts into delivering first-in-class therapeutics for neurological disorders using its expertise. RaQualia, on the other hand, has dedicated efforts to expanding its pipeline as an innovative biotech company for future growth. RaQualia has positioned the neurological disorders field as an important pillar and is actively engaged in utilizing innovative modalities and building a new drug discovery value chain.

Under the terms of the agreement, Nissan Chemical grants RaQualia an exclusive global license with sub-license right for certain know-how in the field of neurological disorders. Nissan Chemical will receive an upfront payment, milestone payments based on progress, and royalties on sublicensing.

RaQualia will leverage Nissan Chemical know-how to discover and develop neurological therapeutics.

This collaboration is part of an initiative to build a drug discovery value chain generated from the combination of both companies' strengths. The integration of Nissan Chemical's proprietary drug discovery know-how with RaQualia's research and development capabilities will lead to the identification of new drug candidates in a short period.

About Nissan Chemical Corporation

Nissan Chemical Corporation contributes to solving social issues providing products and services through four business areas – Performance materials, Agricultural chemicals, Chemicals, and Healthcare. We will acquire new technologies and accelerate growth in each business area by improving and combining core technologies.

Additional information is available at www.nissanchem.co.jp/.

About RaQualia Pharma Inc.

RaQualia Pharma's mission is “We brighten people’s lives through the power of innovation.” RaQualia Pharma strives to deliver new medications for diseases with limited treatment options. Guided by this philosophy, RaQualia Pharma is dedicated to the research and development of new medications through partnerships. RaQualia Pharma, as professionals in drug discovery, is focusing on research and development efforts with a primary focus on patients to create innovative, first-in-class therapeutic medications.

Additional information is available at www.raqualia.com/en/

Contact information for inquiries to Nissan Chemical
Nissan Chemical Corporation Corporate Planning Department Planning Office, Public Relations Group E-mail : pr_cpd@nissanchem.co.jp

Contact information for inquiries to RaQualia Pharma
RaQualia Pharma Inc. Business Management Corporate Affairs E-mail : ask@raqualia.com